Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2021-10-18
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well platinum-based chemotherapy works when given together
with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Drugs used in chemotherapy, such as carboplatin, paclitaxel, and pemetrexed, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. The purpose of this study is to
find out if the combination of chemotherapy in combination with the immune therapy drug
durvalumab would be efficacious and have an acceptable toxicity profile in patients with
advanced non-small cell lung cancer.